Referral Guidance
BrainsWay Deep TMS offers new hope for patients suffering from treatment-resistant Depression / Anxious Depression, OCD, and Smoking Addiction
BrainsWay’s Deep Transcranial Magnetic Stimulation is a well-tolerated, noninvasive treatment with proven efficacy that has been FDA-cleared to treat depression / anxious depression, OCD, and Smoking Addiction.
Using its patented H-Coil technology, Deep TMS™ utilizes magnetic fields to regulate the neural activity of brain structures shown to be associated with mental health conditions. Deep TMS does not require anesthesia and allows patients to incorporate the treatment into their daily routines.
Deep TMS is covered by Medicare and most US private insurers for depression / anxious depression.
Why refer patients to Deep TMS treatment?
Studies have shown that patients with severe MDD or OCD don’t always respond to traditional psychological treatments
Patients who experience recurrent MDD episodes have been found to benefit less from psychotherapy
1,2
Deep TMS has been found to be an effective solution even for treatment-resistant patients with MDD
Many patients do not find significant relief through medication
33% of patients with MDD are resistant to medication, while 52% fail to respond to first-line therapy (STAR*D results)
3
Approximately 50% of patients with OCD are resistant to first-line therapies, including SSRI medication
4
Many patients discontinue medication treatment due to serious side effects
Antidepressant medication frequently causes adverse side effects, such as weight gain, sexual dysfunction, suicidal ideation, insomnia and anxiety.
BrainsWay can provide guidance as you speak with patients about the potential benefits of Deep TMS treatment.
Referral Sourcing: We’ll help you identify which healthcare providers offer Deep TMS in your area and facilitate an introduction. You can also look up our provider listings
Patient Communication Materials: We provide brochures that enable you to discuss the clinical benefits, safety considerations, and treatment protocol with potential patients.
Ongoing Provider Education: BrainsWay orchestrates education on the state of TMS evidence and its complimentary nature to traditional treatment options, through webinars, live symposiums, and other forums.
1. Carter, J.D., et al Patient predictors of response to cognitlve behaviour therapy and interpersonal psychotherapy in a randomised dlnical trial for depression. Journal of Affective Disorders. 128 (2011) 252-261.
2. Carter, J.D., et al Patlent predictors of response to cognitive behaviour therapy and schema therapy for depression. Australian & New Zealand Journal of Psychiatry. 52 (2018) 887·897.
3. Rush AJ, et al Acute and longer-term outcomes In depressed outpatlents requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 163 (2006) 1905-17.
4. Kellner, M. Drug Treatment of obsessive-cofll)ulslve disorder. Dialogues Clln Neuroscl. 2010 Jun; 12(2): 187-197.